E. coli, K. pneumoniae and K. oxytoca community-acquired infections susceptibility to cephalosporins and other antimicrobials in Lebanon.
暂无分享,去创建一个
[1] S. Pournaras,et al. Susceptibility patterns to extended-spectrum cephalosporins among Enterobacteriaceae harbouring extended-spectrum β-lactamases using the updated Clinical and Laboratory Standards Institute interpretive criteria. , 2013, International journal of antimicrobial agents.
[2] G. Araj,et al. A reflection on bacterial resistance to antimicrobial agents at a major tertiary care center in Lebanon over a decade. , 2012, Le Journal medical libanais. The Lebanese medical journal.
[3] G. Araj,et al. In vitro activity of fosfomycin and other antimicrobials against uropathogenic Escherichia coli and Klebsiella pneumoniae at a tertiary care center in Lebanon. , 2012, Le Journal medical libanais. The Lebanese medical journal.
[4] D. Sarkis,et al. [Evolution of susceptibility to antibiotics of Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumanii, in a University Hospital Center of Beirut between 2005 and 2009]. , 2012, Pathologie-biologie.
[5] W. Sweileh,et al. Antibiotic resistance of bacterial strains isolated from patients with community-acquired urinary tract infections: an exploratory study in Palestine. , 2011, Current Clinical Pharmacology.
[6] J. Shin,et al. Prevalence of Plasmid-mediated Quinolone Resistance and Its Association with Extended-spectrum Beta-lactamase and AmpC Beta-lactamase in Enterobacteriaceae , 2011, The Korean journal of laboratory medicine.
[7] S. H. Teo,et al. Aetiology of community-acquired urinary tract infection and antimicrobial susceptibility patterns of uropathogens isolated. , 2011, Singapore medical journal.
[8] Richard Colgan,et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] Luis Martõ. Plasmid-mediated quinolone resistance: an update , 2011 .
[10] A. Corso,et al. Can We Use Imipenem and Meropenem Vitek 2 MICs for Detection of Suspected KPC and Other-Carbapenemase Producers among Species of Enterobacteriaceae? , 2010, Journal of Clinical Microbiology.
[11] P. Nordmann,et al. Spread of OXA-48-mediated resistance to carbapenems in Lebanese Klebsiella pneumoniae and Escherichia coli that produce extended spectrum β-lactamase , 2010, Annals of tropical medicine and parasitology.
[12] H. Rajak,et al. Fluoroquinolones in urinary tract infections: A stu dy on perception analysis of prescribers , 2010 .
[13] P. Edelstein,et al. Specificity of Ertapenem Susceptibility Screening for Detection of Klebsiella pneumoniae Carbapenemases , 2009, Journal of Clinical Microbiology.
[14] M. Dettenkofer,et al. Should We Screen Patients for Extended-Spectrum β-Lactamase–Producing Enterobacteriaceae in Intensive Care Units? , 2009, Infection Control & Hospital Epidemiology.
[15] G. Gerken,et al. [Collateral damage of cephalosporins and quinolones and possibilities for control]. , 2009, Medizinische Klinik.
[16] J. Ayala-Gaytán,et al. [Antibiotic resistance of Escherichia coli from community-acquired urinary tract infections. What antimicrobial to use?]. , 2009, Salud publica de Mexico.
[17] D. Livermore,et al. Plasmids Imparting Sulfonamide Resistance in Escherichia coli: Implications for Persistence , 2008, Antimicrobial Agents and Chemotherapy.
[18] G. Araj,et al. Tigecycline in vitro activity against commonly encountered multidrug-resistant gram-negative pathogens in a Middle Eastern country. , 2008, Diagnostic microbiology and infectious disease.
[19] Atul Kothari,et al. Antibiotic resistance in pathogens causing community-acquired urinary tract infections in India: a multicenter study. , 2008, Journal of infection in developing countries.
[20] A. Oliver,et al. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. , 2008, Archives of internal medicine.
[21] Y. Carmeli,et al. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. , 2007, The Journal of antimicrobial chemotherapy.
[22] J. Morris,et al. Risk Factors for Colonization with Extended-Spectrum β-Lactamase–producing Bacteria and Intensive Care Unit Admission , 2007, Emerging infectious diseases.
[23] R. Theriault,et al. Once daily, oral, outpatient quinolone monotherapy for low‐risk cancer patients with fever and neutropenia , 2006, Cancer.
[24] Z. Daoud,et al. Extended spectrum beta-lactamase producing Enterobacteriaceae in Lebanese ICU patients: epidemiology and patterns of resistance. , 2006, The Journal of general and applied microbiology.
[25] D. Livermore,et al. Resistance among Escherichia coli to sulphonamides and other antimicrobials now little used in man. , 2005, The Journal of antimicrobial chemotherapy.
[26] Robert A. Bonomo,et al. Extended-Spectrum (cid:2) -Lactamases: a Clinical Update , 2005 .
[27] L. Nicolle,et al. Complicated urinary tract infection in adults. , 2005, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.
[28] A. Madan. Use of ciprofloxacin in the treatment of hospitalized patients with intra-abdominal infections. , 2004, Clinical therapeutics.
[29] J. Rodríguez-Baño,et al. Epidemiology and Clinical Features of Infections Caused by Extended-Spectrum Beta-Lactamase-Producing Escherichia coli in Nonhospitalized Patients , 2004, Journal of Clinical Microbiology.
[30] M. Schaller,et al. Cefepime versus Imipenem-Cilastatin for Treatment of Nosocomial Pneumonia in Intensive Care Unit Patients: a Multicenter, Evaluator-Blind, Prospective, Randomized Study , 2003, Antimicrobial Agents and Chemotherapy.
[31] Z. Daoud,et al. [Prevalence and susceptibility patterns of extended-spectrum betalactamase-producing Escherichia coli and Klebsiella pneumoniae in a general university hospital in Beirut, Lebanon]. , 2003, Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia.
[32] D. Paterson. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs). , 2000, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[33] D. Livermore. beta-Lactamases in laboratory and clinical resistance , 1995, Clinical microbiology reviews.
[34] J. D. Conklin. The pharmacokinetics of nitrofurantoin and its related bioavailability. , 1978, Antibiotics and chemotherapy.